Compare radiotherapy versus everolimus for lung and thymus tumors
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study compares two treatment options for somatostatin receptor–positive neuroendocrine tumors from the lung or thymus: radiotherapy versus everolimus. It aims to see which treatment works better and how safe each option is for people whose disease has progressed within the last year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can sign consent for the study.
- Your tumor has been confirmed (biopsy/pathology) as a well- or moderate-grade neuroendocrine tumor from the lung or thymus.
- Your scan must show somatostatin receptors on all the main (measurable) tumor spots, and your disease has progressed on imaging within the past 12 months.
- You must have measurable metastatic or unresectable advanced cancer, and you can be in either first treatment or after up to 2 prior systemic cancer treatments.
- You must be well enough to participate (ECOG 0–1) and have blood work and organ function within required limits.
- You must be able to provide tumor tissue for lab testing (from past samples or a new biopsy if needed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining peptide receptor radionuclide therapy (PRRT) with long-acting somatostatin analogues to see how much radiation reaches the tumor. It is for people with neuroendocrine tumors who meet the standard criteria for PRRT.
This trial compares two daily doses (5 mg vs 10 mg) of everolimus, a targeted therapy, to see which works better and is safer for people with advanced neuroendocrine tumors (NETs). You may qualify if your cancer has grown despite previous treatment and you are in relatively good health.
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This Phase 3 trial tests RYZ101 versus standard of care in people with inoperable, well-differentiated SSTR-positive GI or pancreas neuroendocrine tumors (NETs) that keep growing after Lu-177 SSA. It may help by improving tumor control after your prior targeted radiation treatment.
This trial studies whether it’s helpful to keep taking somatostatin “analog” injections even after your neuroendocrine tumor has started growing despite the usual dose. It also looks at how the next treatment choice (targeted pills or PRRT) fits in for people with non-functional, well-differentiated GEP NET.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.